Recent Press Releases

Baxter Announces Divestiture of Commercial Vaccines Business to Pfizer

DEERFIELD, Ill., July 30, 2014 - Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related...

Pfizer Enters Into Agreement To Acquire Baxter's Portfolio Of Marketed Vaccines

Wednesday, July 30, 2014 - 8:00am EDT Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for...

ASTRAZENECA AGREES STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE

ASTRAZENECA AGREES STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca's...

Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

Second Quarter 2014 GAAP EPS Were $2.01

THOUSAND OAKS, Calif., July 29, 2014 /PRNewswire/ -- Amgen (

Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo

Company's two-booth approach allows customers to see how Roche is partnering with them today and tomorrow

CHICAGO,

GSK's Tanzeum™ is now available in pharmacies in the U.S.

PHILADELPHIA, July 29, 2014 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (alb

Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia

Roche's Gazyvaro approved in Europe for patients with the most common type of leukemia Gazyvaro, the first type II, glycoengineered anti-CD20 monoclonal antibody is now approved in Europe for...

Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo

ABBOTT PARK, Ill., July 28, 2014 /PRNewswire/ -- Clinical laboratories around the world are helping to improve patient care while navigat

Physician and Industry Groups to Discuss Sunshine Act Implementation

Physician and Industry Groups to Discuss Sunshine Act Implementation WASHINGTON, D.C. — The American Association of Neurological Surgeons (AANS) and the Pharmaceutical Research and...

ASTRAZENECA AND ROCHE ANNOUNCE PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTIC TEST FOR AZD9291

ASTRAZENECA AND ROCHE ANNOUNCE PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTIC TEST FOR AZD9291 28 July 2014 AstraZeneca today announced it has entered into collaboration with Roche to develop a...

Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease

Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease Simbrinza provides a convenient option to reduce treatment burden versus...

Generic usage increased to more than 75% in 2013 according to NHS data

Generic usage increased to more than 75% in 2013 according to NHS data · £1.3bn additional cost savings for the NHS · Increased patient access to life saving...

Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -

Novo Nordisk A/S: Novo Nordisk receives positive opinion on Xultophy(r) (IDegLira) from the European regulatory authorities

Bagsvaerd, Denmark, Jul 25, 2014 (GLOBE NEWSWIRE via COMTEX) -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency...

Phase III Trial of Sorafenib in Combination with Capecitabine Does Not Meet Primary Endpoint in Patients with Advanced Breast Cancer

Phase III Trial of Sorafenib in Combination with Capecitabine Does Not Meet Primary Endpoint in Patients with Advanced Breast Cancer Berlin, July 25, 2014 – Bayer HealthCare Pharmaceuticals and...

European Medicines Agency recommends approval of two new treatment options for rare cancers

European Medicines Agency recommends approval of two new treatment options for rare cancers Imbruvica and Zydelig to be used in different forms of blood cancers The European Medicines Agency's...

AbbVie Reports Second-Quarter 2014 Financial Results

- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 (Reports GAAP EPS of $0.68) - Delivers Second-Quarter Revenue of $4.926 Billion, an Increase of 5.0...

HIKMA AGREES TO ACQUIRE BEN VENUE MANUFACTURING SITE ADDING R&D CAPABILITIES AND CAPACITY

HIKMA AGREES TO ACQUIRE BEN VENUE MANUFACTURING SITE ADDING R&D CAPABILITIES AND CAPACITY London, 24 July 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC:...

Bristol-Myers Squibb Company (BMY) Appoints Jitendra Tyagi As India Country Head

Bristol-Myers Squibb Company (BMY) Appoints Jitendra Tyagi As India Country Head Bristol-Myers Squibb (BMS) India appointed Jitendra Tyagi as the BMS India country head. He has successfully performed...